Human telomerase reverse transcriptase peptide (611-626) (tertomotide)
Treatment of pancreatic cancer
|Orphan designation status||
|EU designation number||
|Date of designation||
|May 2009||The sponsorship was transferred to Gemvax A/S, Norway, in May 2009.|
|April 2020||The sponsor’s address was updated in April 2020.|
|May 2020||The sponsorship was transferred to Klifo A/S, Denmark.|
|August 2023||Please note that this product was withdrawn from the Union Register of orphan medicinal products in August 2023 on request of the Sponsor.|
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: